Premium
A Pharmacokinetic Evaluation of the Combined Administration of Triazolam and Fluoxetine
Author(s) -
Wright C. Eugene,
LasherSisson Theresa A.,
Steenwyk Rick C.,
Swanson Carl N.
Publication year - 1992
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1992.tb03617.x
Subject(s) - triazolam , fluoxetine , pharmacokinetics , pharmacology , hypnotic , diazepam , medicine , chemistry , anesthesia , benzodiazepine , receptor , serotonin
The influence of fluoxetine on triazolam pharmacokinetics was studied because of changes in diazepam pharmacokinetics reportedly produced by fluoxetine. Twenty‐four healthy volunteers received a single 0.25‐mg triazolam tablet alone, and another 0.25‐mg tablet after 8 days of fluoxetine therapy 60 mg/day. All subjects received these treatments in the same sequence. Several blood samples were drawn from the subjects after the triazolam doses and were assayed by high‐performance liquid chromatography (HPLC). Blood samples were drawn immediately before the last three fluoxetine doses to determine the concentration of fluoxetine and its metabolite norfluoxetine, also by HPLC. The pharmacokinetics of triazolam did not change significantly when the tablets were administered after multiple doses of fluoxetine. These results indicate that no pharmacokinetic interaction exists between triazolam and fluoxetine or norfluoxetine. However, each patient's clinical response to therapy should be monitored when triazolam tablets and fluoxetine capsules are administered concomitantly.